|
|
PAST EVENTS
|
2008
2008 ASCO Breast Cancer Symposium - September 5-7, 2008 | Washington, DC
Developing predictors of chemotherapy response using gene expression profiling in preoperative clinical trials
Presenter: Dr. L. Pusztai (General Session X)
44th ASCO Annual 2008 Meeting - May 30-June 3, 2008 | Chicago, IL
Combined use of genomic prognostic and treatment response predictors in breast cancer
Presenter: Dr. L. Pusztai (Abstract 527)
Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers
Presenter: Dr. C. Hatzis (Abstract 544)
Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer
Presenter: Dr. W.F. Symmans (Abstract 571)
Inter-pathologist agreement of residual cancer burden (RCB) assessment in breast cancer after treatment with preoperative chemotherapy
Presenter: Dr. F. Peintinger (Abstract 576)
AACR Anual Meeting - April 12-16, 2008 | San Diego, CA
Personalized Medicine: Predictors of Response - Saturday, April 12, 2008, 1:00 - 3:00pm | Room 11A-B, San Diego Convention Center
Residual cancer burden to accurately monitor and identify biomarkers for response
Presenter: Dr. C. Hatzis
The First Annual North American Symposium on Personalized Therapies for Breast Cancer
Jan 19-20, 2008 | Miami, FL
Future directions and emerging technologies with molecular diagnostic as predictors of therapeutic response to individual chemotherapy agents
Presenter: Dr. L. Pusztai
Predictors of response and personalized approaches to selecting patients for adjuvant and neo-adjuvant hormonal therapy in ER+ breast cancer
Presenter: Dr. L. Pusztai
2007
Association for Molecular Pathology 2007 Annual Meeting
Los Angeles, CA
Gene Expression Testing In Breast Cancer - Panel Discussion
Presenter: Dr. W.F. Symmans
ASCO Breast Cancer Symposium 2007
San Francisco, CA
Estrogen receptor related gene expression predicts sensitivity to endocrine therapy, but is not prognostic
Presenter: Dr. W.F. Symmans [ Abstract ]
Combined use of genomic prognostic and treatment response predictors in lymph node-negative breast cancer
Presenter: Dr. L. Pusztai [ Abstract ]
Initial cancer burden as a predictor of relapse-free survival in breast cancer patients
Presenter: Dr. F. Peintinger [ Abstract ]
ASCO 2007
Chicago, IL
Technology driven decision making in oncology.
Presenter: Dr. L. Pusztai
Gene expression profiling to predict response to anthracyclines.
Presenter: Dr. L. Pusztai [ Abstract ]
HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer (Abstract No: 548).
Presenter: Dr. L. Pusztai [ Abstract ]
The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab (Abstract No: 533).
Presenter: Dr. F. Peintinger [ Abstract ]
AACR 2007
Los Angeles, CA
Building A Multi-Treatment Response Predictor in Breast Cancer.
Presenter: Dr. C. Hatzis [ Abstract ]
Vav3, A Rho GTPase Guanine Nucleotide Exchange Factor, Represents A Potential Novel Therapeutic Target For Breast Cancer.
Presenter: Dr. L. Pusztai [ Abstract ]
Discovery of Pharmacogenomic Predictors in Phase II Clinical Trials: Limitations and Alternatives.
Presenter: Dr. L. Pusztai [ Abstract ]
2006
SABCS 2006
San Antonio, TX
Genomic Predictor of Benefit from Endocrine Therapy Also Predicts Response to Chemotherapy.
Presenter: Dr. C. Hatzis [ Abstract ]
A Genomic Index of Estrogen Receptor Reporter Genes Predicts Benefit from Adjuvant Endocrine Therapy Independent of Baseline Prognosis.
Presenter: Dr. W.F. Symmans [ Abstract ]
Microtubule Associated Protein (MAP)-Tau Is A Bifunctional Predictor of Endocrine Sensitivity And Chemotherapy Resistance In ER-Positive Breast Cancer.
Presenter: Dr. L. Pusztai [ Abstract ]
Correlation Between Residual Cancer Volume And MDACC Genomic Response Predictor Score In Breast Cancer Patients Treated With Preoperative Chemotherapy.
Presenter: Dr. L. Pusztai [ Abstract ]
ESMO 2006
Istanbul, Turkey
Is Molecular Profiling Ready For Use In Clinical Decision Making? Yes.
Presenter: Dr. L. Pusztai [ Abstract ]
International Scientific Symposium 2006
Paris, France
Predictive Biomarkers for the Efficacy of Chemotherapy.
Presenter: Dr. L. Pusztai
ASCO's Development of Molecular Therapeutics in Breast Cancer Conference
Aspen, CO
Gene Expression Profiling for Prediction of Response or Resistance to Treatment.
Presenter: Dr. L. Pusztai
ASCO 2006
Atlanta, GA
Pharmacogenomic Predictor of Complete Response to Preoperative Paclitaxel and 5-fluorouracil, Doxorubicin, Cyclophosphamide Chemotherapy In Breast Cancer.
Presenter: Dr. L. Pusztai [ Abstract ]
A New Measurement of Residual Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy.
Presenter: Dr. W.F. Symmans [ Abstract ]
AACR 2006
Washington, DC
Development of A Pharmacogenomic Predictor of Complete Response to Preoperative Paclitaxel-FAC Chemotherapy for Breast Cancer.
Presenter: Dr. L. Pusztai
US & Canadian Academy of Pathology Annual Meeting 2006
Atlanta, GA
Predictive Biomarkers Of Breast Cancer Response to Neoadjuvant Chemotherapy and Their Relationship to Pathologic Assessment of Residual Disease.
Presenter: Dr. W.F. Symmans [ Abstract ]
2005
SABCS 2005
San Antonio, TX
Affymetrix Gene Chip Profile Predicts Pathologic Complete Response to Preoperative Paclitaxel/FAC Chemotherapy in Breast Cancer.
Presenter: Dr. L. Pusztai [ Abstract ]
Measurements of Estrogen Receptor and Reporter Genes from Microarrays Determine Receptor Status and Time to Recurrence Following Adjuvant Tamoxifen Therapy.
Presenter: Dr. W.F. Symmans [ Abstract ]
Expression Level of Estrogen Receptor Gene and Three ER-Related Genes in Metastatic ER-Positive Breast Caner Compared with Response to Endocrine Therapy.
Presenter: Dr. W.F. Symmans [ Abstract ]
|
|
|
|
